Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients... There are many difficulties associated with the late stages of Parkinson's disease (PD), but psychosis and agitation may be the most disturbing for both patients and care givers, and often precipitate the pivotal decision for long-term nursing home placement. While the addition of antipsychotic drugs or the withdrawal of antiparkinsonian drugs may improve the behavioral problem, these strategies usually worsen the motor difficulties. Clozapine has been studied in PD for over a decade, and while it appears to be effective, there are safety and tolerability concerns associated with it. In addition, in New Jersey, Medicaid no longer pays for the home blood draws that are required for home-bound patients. This led to a situation in which we had patients who needed to stop clozapine and begin an alternative therapy. Because quetiapine seems particularly well suited to patients with PD based on in vitro and in vivo studies we have begun to try this medication in PD patients who need to stop clozapine. This article reports three case histories of patients with PD, confusion and dopamimetic psychosis who had been previously managed with clozapine and who were successfully switched to quetiapine. At doses from 12.5 to 150 mg/day quetiapine was well tolerated, resulting in behavioral improvement and no real increase in parkinsonism. These case histories raise the possibility that quetiapine may represent a viable alternative to clozapine in PD patients with dopamimetic psychosis and behavioral disturbances. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/quetiapine-as-an-alternative-to-clozapine-in-the-treatment-of-J0FQcjStSI
Publisher
Springer Journals
Copyright
Copyright © 1999 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022360027358
Publisher site
See Article on Publisher Site

Abstract

There are many difficulties associated with the late stages of Parkinson's disease (PD), but psychosis and agitation may be the most disturbing for both patients and care givers, and often precipitate the pivotal decision for long-term nursing home placement. While the addition of antipsychotic drugs or the withdrawal of antiparkinsonian drugs may improve the behavioral problem, these strategies usually worsen the motor difficulties. Clozapine has been studied in PD for over a decade, and while it appears to be effective, there are safety and tolerability concerns associated with it. In addition, in New Jersey, Medicaid no longer pays for the home blood draws that are required for home-bound patients. This led to a situation in which we had patients who needed to stop clozapine and begin an alternative therapy. Because quetiapine seems particularly well suited to patients with PD based on in vitro and in vivo studies we have begun to try this medication in PD patients who need to stop clozapine. This article reports three case histories of patients with PD, confusion and dopamimetic psychosis who had been previously managed with clozapine and who were successfully switched to quetiapine. At doses from 12.5 to 150 mg/day quetiapine was well tolerated, resulting in behavioral improvement and no real increase in parkinsonism. These case histories raise the possibility that quetiapine may represent a viable alternative to clozapine in PD patients with dopamimetic psychosis and behavioral disturbances.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 1, 2004

References

  • Risk factors for nursing home placement in advanced Parkinson's disease
    Goetz, CG; Stebbins, GT.
  • Low dose clozapine in the treatment of dopaminergic psychosis in Parkinson's disease
    Ruggieri, S; De Pandis, MF; Bonamartini, A; Vacca, L; Stocchi, F
  • Clozapine for the treatment of psychosis in Parkinson's disease: a review
    Auzou, P; Ozsancak, C; Hannequin, D; Moore, N; Augustin, P.
  • Drug treatment of Parkinson's disease in the 1990s: achievements and future possibilities
    Hughes, AJ.
  • Risperidone versus clozapine in the treatment of psychosis in six patient with Parkinson's disease and other akinetic-rigid syndromes
    Rich, SS; Friedman, JH; Ott, BR.
  • Risperidone in Parkinson's disease
    Ford, B; Lynch, T; Greene, P.
  • Neuroleptic sensitivity to risperidone in Lewy body dementia
    McKeith, IG; Ballard, BG; Harrison, RWS.
  • Risperidone for hallucinations in levodopa-treated Parkinson's disease patients
    Meco, G; Alessandria, A; Bonifati, V; Giustine, P.
  • Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
    Meco, G; Alessandri, A; Giurtine, P; Bonifati, V.
  • The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease
    Workman, RH; Orengo, CA; Bakey, AA; Molinari, VA; Kunik, ME.
  • Olanzapine in the treatment of dopaminomimetic psychosis in patients
    Wolters, EC; Jansen, EN; Tuynman-Qua, HG; Bergmans, PL.
  • Olanzapine can worsen parkinsonism
    Jimenez-Jimenez, FJ; Tallon-Barranco, A; Orti-Pareja, M; Zurdo, M; Porta, J; Molina, JA.
  • Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
    Friedman, J.
  • Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
    Arnt, J; Skarsfeldt, T.
  • Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease
    Parsa, M; Bastini, B.
  • Long-term effects of quetiapine fumarate in Parkinsonism complicated by psychosis
    Jancos, JL; Evatt, ML; Jewart, D.
  • Behavioral complications of drug treatment of Parkinson's disease
    Cummings, JL.